Big Pharma Split Corp. (PRM.TO)
CAD 11.7
(2.27%)
CAD 11.7
(2.27%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 11.85 Million | 1.12 Million | -9 Million | 4.34 Million | 8.67 Million | 1.27 Million |
| Net Income | -645.35 Thousand | 2.38 Million | 4.2 Million | -217.38 Thousand | 2.57 Million | 2.1 Million |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 9658.00 | 175.38 Thousand | -154.29 Thousand | -31.68 Thousand | -3012.00 | -53.96 Thousand |
| Other non-cash items | 12.49 Million | -1.43 Million | -13.05 Million | 4.59 Million | 6.1 Million | -780.21 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | -3.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -12.47 Million | -1.73 Million | 10.19 Million | -4.65 Million | -8.56 Million | -2.7 Million |
| Debt repayment | -5.48 Million | -481.15 Thousand | -5.74 Million | -1.23 Million | -2.82 Million | - |
| Dividends payments | -1.53 Million | -1.86 Million | -2.21 Million | -1.23 Million | -1.48 Million | -2.25 Million |
| Common Stock Repurchased | -10.8 Million | - | - | -2.92 Million | -6.48 Million | -456.08 Thousand |
| Common Stock Issuance | 445.12 Thousand | 399.77 Thousand | 7.57 Million | - | - | - |
| Other Financing Activities | -5.04 Million | 478.79 Thousand | 5.45 Million | -2.92 Million | -6.48 Million | -191 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 9658.00 | 175.38 Thousand | -154.29 Thousand | -31.68 Thousand | -3012.00 | -53.96 Thousand |
| Cash at beginning of period | 819.21 Thousand | 1.42 Million | 230.99 Thousand | 536.05 Thousand | 417.07 Thousand | 1.84 Million |
| Cash at end of period | 204.19 Thousand | 819.21 Thousand | 1.42 Million | 230.99 Thousand | 536.05 Thousand | 417.07 Thousand |
| Capital Expenditure | -3.00 | - | - | - | - | - |
| Effect of forex changes on cash | -2638.00 | -1740.00 | 5356.00 | -1457.00 | 9131.00 | 10.39 Thousand |
| Net cash flow / Change in cash | -615.02 Thousand | -610.61 Thousand | 1.19 Million | -305.06 Thousand | 118.98 Thousand | -1.42 Million |
| Free Cash Flow | 11.85 Million | 1.12 Million | -9 Million | 4.34 Million | 8.67 Million | 1.27 Million |
| Breakdown | 2024 Q2 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 1.23 Million | -78.05 Thousand | -645.35 Thousand | -39.02 Thousand | -567.3 Thousand | -283.65 Thousand |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 16.98 Thousand | 9660.00 | 9658.00 | 4830.00 | -2.00 | -1.00 |
| Other non-cash items | -1.67 Million | -721.79 Thousand | 12.49 Million | 678.48 Thousand | 936.54 Thousand | 5.56 Million |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | 4.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -90.83 Thousand | -1.22 Million | -12.47 Million | -741.31 Thousand | -10.67 Million | -5.49 Million |
| Debt repayment | -737.67 Thousand | -131.56 Thousand | -5.48 Million | - | -5.35 Million | - |
| Dividends payments | -804.03 Thousand | -736.08 Thousand | -1.53 Million | -494.8 Thousand | -803.8 Thousand | -559.48 Thousand |
| Common Stock Repurchased | -24.46 Thousand | -806.57 Thousand | -10.8 Million | -403.28 Thousand | -4.51 Million | -2.25 Million |
| Common Stock Issuance | - | 445.12 Thousand | 445.12 Thousand | - | - | - |
| Other Financing Activities | - | 156.78 Thousand | -5.04 Million | 156.78 Thousand | -2.67 Million | -2.67 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 16.98 Thousand | 9660.00 | 9658.00 | 4830.00 | -2.00 | -1.00 |
| Cash at beginning of period | 204.19 Thousand | 397.5 Thousand | 819.21 Thousand | - | 819.21 Thousand | - |
| Cash at end of period | 1.59 Million | 204.19 Thousand | 204.19 Thousand | -96.65 Thousand | 397.5 Thousand | -210.85 Thousand |
| Capital Expenditure | 4.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | 370.00 | -2638.00 | 370.00 | -1689.00 | -1689.00 |
| Net cash flow / Change in cash | 1.38 Million | -193.31 Thousand | -615.02 Thousand | -96.65 Thousand | -421.7 Thousand | -210.85 Thousand |
| Free Cash Flow | -422.1 Thousand | -790.18 Thousand | 11.85 Million | 644.28 Thousand | 369.24 Thousand | 5.28 Million |
YVIT
FDGMF
CGABL
0GC0
1003
DAR